IL4R抗体;IL4R Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13618(IL4R Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P13618(IL4R Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

The interleukin-4 receptor (IL-4R) is a cell-surface protein that plays a central role in regulating immune responses, particularly those mediated by type 2 helper T (Th2) cells. It exists in two forms: Type I (IL-4Rα paired with the common gamma chain γc) binds IL-4. while Type II (IL-4Rα combined with IL-13Rα1) interacts with both IL-4 and IL-13. These cytokines drive allergic inflammation by promoting B-cell activation, IgE production, eosinophil recruitment, and tissue remodeling. Dysregulated IL-4R signaling is implicated in Th2-mediated diseases such as asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis.

Targeting IL-4Rα with monoclonal antibodies offers a strategic approach to block signaling from both IL-4 and IL-13. Dupilumab, the first FDA-approved IL-4Rα antibody (2017), demonstrates efficacy in multiple allergic and type 2 inflammatory conditions by inhibiting downstream pathways like JAK-STAT. Other candidates, including tralokinumab, have shown more limited success, highlighting the complexity of cytokine redundancy in these diseases. Emerging research explores IL-4R blockade in fibrotic disorders and cancer immunotherapy, where IL-4/IL-13 may suppress antitumor immunity. While generally well-tolerated, long-term safety profiles and predictive biomarkers for treatment response remain active investigation areas. The dual cytokine inhibition strategy positions IL-4R antibodies as versatile tools for modulating Th2-driven pathology.